الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 57 |  |  |
| | | from | 57 | | |
Abstract
In children, iron deficiency anaemia (IDA) is a difficult medical issue. It is the most prevalent nutritional inadequacy worldwide, particularly in underdeveloped nations. According to World health organization (WHO) estimates from 2001, 48% of children aged 5 to 14 and 30% of toddlers aged 0 to 4 were anaemic. The causes of iron deficiency anaemia in children include higher requirements brought on by fast growth and insufficient intake of iron.
Children were particularly susceptible to iron deficiency anaemia’s devastating effect. Growth retardation, lowered immunity, lower IQ, less capacity for physical activity, more fatigue and poorer psychomotor, cognitive, and academic performance are some of the negative drawbacks.
Symptoms rarely manifest itself in children with mild IDA. Pica, fatigue, irritability, heart palpitations, shortness of breath, and paleness are among the symptoms that maybe displayed by some of them. Tachycardia and heart failure can occur in children with severe iron deficiency anaemia. Preventing iron deficit in infants or correctly diagnosing and treating iron deficiency early on is crucial.
Recent studies have led to the suggestion that lactoferrin could be a viable treatment for this worldwide health issue. Lactoferrin is a non-haem protein that binds iron and is related to serum transferrin, which is a protein that carries iron throughout the body. It is found in milk, tears, nasal and bronchial secretions, saliva, and vast amounts are produced by the mammary glands.
Lactoferrin has been shown to retain iron over a wider pH range and have 300-fold greater affinity to iron than serum transferrin. Evidence also showed that it has an effect on iron homeostasis by boosting ferritin storage and iron export from the GIT.
Patients treated with amino acid chelated iron reportedly had fewer and milder gastrointestinal adverse effects.
In order to treat iron deficiency anaemia in children aged 2-6, the current research compared the effectiveness and adherence of two iron preparations: iron chelated with amino acids on the one hand, and a combination of Ferrous Fumerate, Lactoferrin, and Vitamin C on the other.
This was prospective research, conducted in Alexandria University Children’s Hospital on 100 kids aged 2-6 years old separated into two group: (group A): 50 children received a combination of ferrous fumerate, vitamin c and lactoferrin daily for six weeks, (group B): 50 children received iron chelated with amino acids once daily for six weeks. All children were exposed to: Full history taking, complete physical examination, and Investigation.
The study’s primary findings showed that:
• 54% of group A were males, while 46% of group B were males with no statistically significant difference (χ2 = 0.64, p= 0.424).
• The average age of group A was (4.16 ± 1.17 years) and the mean for group B was (4.49 ± 1.2years), the difference lacked statistical significance (t= -1.371, p= 0.174